NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches
Newsfile Corp•21/10/2026•10:17 ET
2
Key Highlights
- ➤NeOnc scheduled FDA End-of-Phase 1 Type B meeting on November 17, 2026 for NEO212
- ➤NeOnc signed nonbinding research MoU with Department of Health Abu Dhabi
- ➤Two children in Abu Dhabi receive investigational NEO100 under Compassionate Care program
- ➤First Abu Dhabi Bank executive Ali Alabedin joined NeOnc board of directors
- ➤NeOnc short interest rose 45% to 757,739 shares as of September 30
Compassionate care for children in Abu Dhabi, a new research MoU and a senior banking appointment add momentum to NeOnc's development story
Houston, Texas--(Newsfile Corp. - October 21, 2026) - As NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) prepares for an upcoming FDA meeting, its work in Abu Dhabi is bringing that human side of biotechnology into focus.
Get started
Create a free account to read the full story.